The FDA Is About to Approve the First New Hair Loss Drug in 30 Years (And It Works Like RU58841

Breezula (Clascoterone) just dropped Phase 3 results showing up to 539% more hair growth vs placebo — making it potentially the first new FDA-approved hair loss drug in over 30 years. But what does that number actually mean, and is it as good as it sounds?

In this video I break down everything you need to know about clascoterone: how it works, what the trial data actually says, and how it compares to RU58841 — a compound I've personally been using for 7 years that works on the exact same mechanism. If you've been scared off finasteride because of the side effects, this one is worth paying attention to.

We cover:
✔ How clascoterone blocks DHT at the follicle receptor without systemic hormonal exposure
✔ The real story behind the Phase 3 SCALP 1 & SCALP 2 trial numbers
✔ Breezula vs RU58841 — binding affinity, potency, and safety compared honestly
✔ When it could realistically reach FDA approval
✔ What else is coming in the next wave of hair loss treatments
I've used finasteride, RU58841, minoxidil, and topical finasteride personally. No fluff, no supplement ads — just the science and my honest take.

Видео The FDA Is About to Approve the First New Hair Loss Drug in 30 Years (And It Works Like RU58841 канала Spencer Gilmore